DEBORA ARGETSINGER: Open Payments
NPI 1376931717 · WYOMING, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,254 in 55 payments from 16 companies in 2025. Trend: 2023 $42 · 2024 $2,667 · 2025 $3,254
Travel & lodging: $1,701Food & beverage: $1,402Consulting: $150
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 11 | $1,976 |
| ABBVIE INC. | 24 | $479 |
| GENZYME CORPORATION | 4 | $202 |
| Biogen, Inc. | 1 | $150 |
| MDD US Operations, LLC | 1 | $101 |
| Novartis Pharmaceuticals Corporation | 2 | $70 |
| ACADIA Pharmaceuticals Inc | 2 | $41 |
| Neurelis, Inc. | 1 | $38 |
| UPSHER-SMITH LABORATORIES LLC | 1 | $33 |
| Celgene Corporation | 2 | $30 |
Products named: INFINITY, QULIPTA, PROCLAIM, UBRELVY, TYSABRI, KESIMPTA, NUPLAZID, VALTOCO.
Industry payments across MI — which companies pay providers there.
